U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641049) titled 'Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer' on June 06.
Brief Summary: This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostat...